Research and Development

Showing 15 posts of 9616 posts found.

janssen_latest_logo_on_sign_closer

Darzalex “significantly reduces” disease progression and death in multiple myeloma at ASH 2018

December 5, 2018 Research and Development ASH 2018, Janssen, darzalex, multiple myeloma, pharma

Janssen has taken the opportunity at the American Society of Hematology (ASH) Annual Meeting 2018 to unveil new Phase 3 …

Pfizer’s biosimilar proves non-inferior to rituximab in lymphoma at ASH 2018

December 4, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ASH 2018, Pfizer, haemophilia

Joining the chorus of data presentations at the American Society of Hematology (ASH) Annual Meeting 2018, Pfizer has announced new …
shutterstock_243110086

Hemlibra shows “clinically meaningful” bleed control in paediatric haemophilia A patients

December 4, 2018 Manufacturing and Production, Research and Development ASH 2018, Hemlibra, Roche, haemophilia, pharma

In another reveal at the American Society of Hematology (ASH) Annual Meeting 2018, Roche unveiled new Phase 3 findings for …
institute_of_cancer_research

Cancer drug access for NHS patients is slowing, ICR reports

December 4, 2018 Manufacturing and Production, Research and Development, Sales and Marketing Cancer, ICR, Institute of Cancer Research, NHS, NICE, UK, pharma

A new report from the Institute of Cancer Research (ICR) has indicated that NHS patients in the UK are suffering …
gilead-sciences

Gilead’s CAR-T therapy Yescarta shows two-year response duration in large B-cell lymphoma

December 3, 2018 Research and Development, Sales and Marketing ASH 2-18, CAR-T, Cancer, Gilead, Yescarta, leukaemia, pharma

Gilead has gone head to head with Novartis at the American Society of Hematology (ASH) Annual Meeting 2018, meeting the …
abbvie_0

AbbVie’s Venclyxto combo beats standard of care in chronic lymphocytic leukaemia

December 3, 2018 Research and Development, Sales and Marketing ASH 2018, AbbVie, Cancer, Venclyxto, leukaemia, pharma

AbbVie has taken the opportunity at the American Society of Hematology (ASH) Annual Meeting 2018 to reveal new data on …

Novartis unveils strong longer-term Kymriah data at ASH 2018

December 3, 2018 Research and Development, Sales and Marketing ASH 2018, Cancer, Kymriah, Novartis, leukaemia, pharma

Novartis has lifted the curtain on longer-term analysis data for its CAR-T therapy Kymriah (tisagenlecleucel) at the American Society of …
brexit_flag

83% in healthcare say UK will not be attractive for R&D and manufacturing post-Brexit

November 30, 2018 Medical Communications, Research and Development R&D, UK, brexit, pharma

As the Brexit crisis continues to spiral, new findings from GlobalData reveal that 83% of healthcare professionals in the UK …
genentech_web

Roche’s Genentech to acquire inflammatory drug discovery firm Jecure

November 28, 2018 Research and Development, Sales and Marketing Genentech, Jecure, Roche, liver disease, nash, pharma

Roche’s subsidiary Genentech has finalised a definitive agreement to acquire Jecure, a US-based biotech which focuses on the discovery of …
shutterstock_204190579

UK cervical cancer screening rates fall to 21-year low

November 28, 2018 Medical Communications, Research and Development Cancer, NHS, UK, cervical cancer, pharma

A report by NHS Digital has revealed that cervical cancer screening coverage has fallen to 71.4%, down from 72% in …
epipen

Teva’s EpiPen generic retails for same price as Mylan’s own

November 28, 2018 Research and Development, Sales and Marketing Mylan, Teva, epipen, pharma

Israeli generics firm Teva has revealed the price tag of its generic version of Mylan’s EpiPen epinephrine auto-injector, and, at …
bayercross3

Bayer’s Jivi approved in Europe for previously treated haemophilia A

November 28, 2018 Research and Development, Sales and Marketing Bayer, Jivi, haemophilia, pharma

Bayer has revealed that its recombinant Factor VIII (rFVIII) replacement therapy Jivi, also known as BAY94-9027, has received approval from …
takeda_usa_pharmaceuticals_u

European approval for Takeda’s Alunbrig in ALK+ advanced non-small cell lung cancer

November 27, 2018 Research and Development, Sales and Marketing Alunbrig, Cancer, Takeda, lung cancer, pharma

Takeda’s Alunbrig (brigatinib) has been granted marketing approval by the European Commission as a monotherapy to treat anaplastic lymphoma kinase-positive …
The Gateway to Local Adoption Series

Latest content